Skip to main content

Security report for taro.com

Taro Pharmaceutical Industries Ltd. · Healthcare · United States

Medium risk. 4 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

75/100

Risk levelMedium

0–100, higher is better. How it is calculated

Taro Pharmaceutical Industries Ltd. is a well-established pharmaceutical company specializing in topical prescription products and other pharmaceutical offerings. The company is now a wholly owned subsidiary of Sun Pharma, a global healthcare leader. The website reflects a corporate presence with sections dedicated to products, research, investor relations, and affiliated sites. The target audience includes healthcare professionals, investors, and consumers seeking pharmaceutical products. The business model focuses on pharmaceutical manufacturing, research, and distribution with a strong market position supported by its parent company Sun Pharma. Technically, the website is built on Drupal 7 with legacy jQuery libraries and uses several JavaScript plugins for UI components. The site is moderately optimized for mobile devices and has a good design and navigation structure. However, some technical debt is evident due to outdated libraries and lack of modern security headers. Hosting appears to be managed with AT&T DNS services, and no advanced analytics or tracking services were detected. From a security perspective, the site uses HTTPS (implied by the domain and typical corporate practice), but lacks DNSSEC and security headers. The WHOIS data shows a long-established domain with appropriate domain locks, indicating legitimacy. No explicit security or incident response policies are published, and no vulnerability disclosure or security.txt files were found. The site lacks a cookie consent mechanism, which may impact privacy compliance. Overall, the website is professional and trustworthy but could improve its security posture and privacy compliance. Strategic recommendations include upgrading outdated libraries, enabling DNSSEC, implementing security headers, and adding cookie consent mechanisms to enhance user trust and regulatory compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

4 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching taro.com

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Security headers
60
Email security
87
DNS health
85
Network security
100
GDPR outside view
53
Average
75

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Taro Pharmaceutical Industries operates in the healthcare sector with a focus on pharmaceutical manufacturing and research. Its ownership by Sun Pharma positions it strongly in the global pharmaceutical market. The company maintains multiple subsidiaries targeting different geographic markets including the USA, Canada, Israel, and international markets. The website supports investor relations and corporate communications, indicating a transparent and mature business model. The partnership ecosystem includes Sun Pharma and affiliated companies like Chattem Chemicals. The company targets healthcare professionals, investors, and consumers, leveraging its research capabilities and product portfolio to maintain competitive advantage. Growth indicators include recent merger announcements and active investor communications.

Security posture

The current security posture is moderate but with notable gaps. The domain is secured with transfer and update prohibitions, indicating good domain management. However, the absence of DNSSEC and security headers reduces protection against DNS spoofing and common web attacks. The use of outdated jQuery 1.7.2 introduces potential vulnerabilities. No public security or incident response policies are available, and no dedicated security contact channels were found. Privacy compliance is partial, lacking cookie consent mechanisms. Overall, the site is functional and legitimate but requires improvements to meet modern security and privacy standards.

Recommendations

  1. Enable DNSSEC on the domain to enhance DNS security and prevent spoofing.
  2. Upgrade all JavaScript libraries, especially jQuery, to the latest secure versions to mitigate known vulnerabilities.
  3. Implement standard security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security.
  4. Add a cookie consent banner and clearly document cookie usage to improve privacy compliance.
  5. Publish a security policy and incident response contact information to enhance transparency and trust.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Taro Pharmaceutical Industries Ltd.
Description
Taro Pharmaceutical Industries is a pharmaceutical company specializing in topical prescription products and other pharmaceutical offerings. It is now a privately held company wholly owned by Sun Pharma, a global healthcare company with innovative therapies, generic medicines, and consumer healthcare products.
Key services
Pharmaceutical product manufacturing, Research and development, Investor relations
Content quality
good
Branding
consistent

Technology

Stack
jQuery 1.7.2, Drupal 7, jQuery DC Mega Menu, jQuery mmenu, jQuery zAccordion, easyResponsiveTabs
Frameworks
Drupal 7
Performance
moderate
Mobile
good
Accessibility
basic
SEO
basic

Security

Observed score
55/100
Good practices seen
  • Domain status includes clientTransferProhibited and serverUpdate/Delete/TransferProhibited flags

Analytics and tracking

Tracking level
minimal
Privacy practices
basic

Advertising

Transparency
poor

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a corporate pharmaceutical site with clear business focus.
  2. No signs of blocking or WAF interference.
  3. Uses older Drupal 7 CMS and legacy jQuery versions.
  4. No explicit privacy cookie banner or consent mechanism found.
  5. WHOIS data supports legitimacy and domain ownership transparency.
  6. No exposed emails or phone numbers found in the HTML content.
  7. Contact is primarily via contact form.
  8. No social media links explicitly found in the HTML content.
  9. No security.txt or vulnerability disclosure page detected.
Technical notes

Notes

The website is built on Drupal 7 CMS, which is an older platform but still widely used. The front-end relies on jQuery 1.7.2 and several jQuery plugins for UI elements like mega menus, responsive tabs, and accordions. The site uses CSS imports and JavaScript files hosted on the same domain, indicating self-hosted assets. The site is mobile responsive with a dedicated mobile menu. Performance is moderate, with no explicit performance optimization scripts detected. SEO is basic with meta tags and RSS feed links present. Accessibility features are minimal but include skip links and basic ARIA roles. The hosting provider is not explicitly stated but DNS nameservers suggest AT&T infrastructure. The site lacks modern security headers and DNSSEC, which are technical risks. Overall, the infrastructure is functional but could benefit from modernization and security enhancements.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with taro.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review taro.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.